Differential Healing After Sirolimus, Paclitaxel and Bare Metal Stent Placement in Combination with PPARγ Agonists: Requirement for mTOR/Akt2 in PPARγ Activation

RATIONALE: Sirolimus- (SES) and paclitaxel-eluting coronary stents (PES) are used to reduce restenosis, but have different sites of action. The molecular targets of sirolimus (SRL) overlap with those of the PPARγ agonist, rosiglitazone (RSG), but the consequence of this interaction on endothelializa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Circ Res
Principais autores: Finn, Aloke V., John, Michael, Nakazawa, Gaku, Polavarapu, Rohini, Karmali, Vinit, Xu, Xin, Cheng, Qi, Davis, Talina, Raghunathan, Chitra, Acampado, Eduardo, Ezell, Tucker, Lajoie, Scott, Eppihimer, Michael, Kolodgie, Frank D., Virmani, Renu, Gold, Herman Kalman
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4492118/
https://ncbi.nlm.nih.gov/pubmed/19797172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCRESAHA.109.200519
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados